Aug 24, 2023, 18:13
Joachim Koch: We evolved and implemented a novel HPLC method to guide selection of antibody drug candidates.
Quoting Joachim Koch, the Vice President of Discovery Research & Translational Immunology at Affimed, on LinkedIn:
”Our latest paper is out in mAbs:
The paper describes how we evolved and implemented a novel HPLC method to guide selection of antibody drug candidates. In particular, this method allows for more physiological estimation of the serum half-life of drug candidates derived from our ROCK® platform reducing the need for cumbersome and costly mouse PK studies.”
For the article click here.
Source: Joachim Koch/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 22, 2024, 05:31
Dec 22, 2024, 05:05